Want to see NBIX full AI Analyst Report?

Neurocrine (NBIX) Stock Forecast & Price Target

1,624 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NBIX Analyst Ratings

Strong Buy

21 Buy

3 Hold

0 Sell

Based on 24 analysts giving stock ratings to

Neurocrine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NBIX Stock 12 Month Forecast

Average Price Target

$200.87

▲(14.28% Upside)

Based on 24 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is $200.87 with a high forecast of $246.00 and a low forecast of $155.00. The average price target represents a 14.28% change from the last price of $175.77.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"127":"$127","157":"$157","187":"$187","217":"$217","247":"$247"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":246,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$246.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":200.8695652173913,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$200.87</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":155,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$155.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[127,157,187,217,247],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,167.77,173.7876923076923,179.8053846153846,185.82307692307694,191.84076923076924,197.85846153846154,203.87615384615384,209.89384615384614,215.91153846153847,221.92923076923077,227.94692307692307,233.9646153846154,239.9823076923077,{"y":246,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,167.77,170.3161204013378,172.8622408026756,175.40836120401337,177.9544816053512,180.50060200668898,183.04672240802677,185.59284280936456,188.13896321070234,190.68508361204013,193.23120401337792,195.77732441471574,198.32344481605352,{"y":200.8695652173913,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,167.77,166.7876923076923,165.8053846153846,164.82307692307694,163.84076923076924,162.85846153846154,161.87615384615384,160.89384615384617,159.91153846153847,158.92923076923077,157.94692307692307,156.9646153846154,155.9823076923077,{"y":155,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":128,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":143.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.63,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.38,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.56,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.78,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.77,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$246.00

Average Price Target$200.87

Lowest Price Target$155.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sean Laaman

Morgan Stanley

$191→$193

Hold

9.80%

Upside

Assigned

07/23/26

Morgan Stanley Issues a Hold Rating on Neurocrine (NBIX)

Yatin Suneja

Guggenheim

$175→$200

Buy

13.79%

Upside

Reiterated

07/21/26

Neurocrine price target raised to $200 from $175 at GuggenheimNeurocrine price target raised to $200 from $175 at Guggenheim

Mohit Bansal

Wells Fargo

$175→$200

Buy

13.79%

Upside

Assigned

07/17/26

Wells Fargo Remains a Buy on Neurocrine (NBIX)

Tazeen Ahmad

Bank of America Securities

$199

Buy

13.22%

Upside

Reiterated

07/15/26

Bank of America Securities Reaffirms Their Buy Rating on Neurocrine (NBIX)

Danielle Brill

Truist Financial

$155→$200

Buy

13.79%

Upside

Reiterated

07/13/26

Neurocrine price target raised to $200 from $155 at TruistNeurocrine price target raised to $200 from $155 at Truist

Laura Chico

Wedbush

$176→$185

Buy

5.25%

Upside

Reiterated

07/13/26

Analysts Are Bullish on These Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Neurocrine (NBIX)

Evan Seigerman

BMO Capital

$144→$170

Hold

-3.28%

Downside

Reiterated

07/13/26

Neurocrine price target raised to $170 from $144 at BMO CapitalNeurocrine price target raised to $170 from $144 at BMO Capital

Brian Abrahams

RBC Capital

$183→$195

Buy

10.94%

Upside

Reiterated

07/07/26

Neurocrine price target raised to $195 from $183 at RBC CapitalNeurocrine price target raised to $195 from $183 at RBC Capital

Akash Tewari

Jefferies

$200

Buy

13.79%

Upside

Reiterated

06/30/26

Neurocrine (NBIX) Receives a Buy from Jefferies

Ashwani Verma

UBS

$182→$208

Buy

18.34%

Upside

Reiterated

06/30/26

Neurocrine price target raised to $208 from $182 at UBSNeurocrine price target raised to $208 from $182 at UBS

Yigal Nochomovitz

Citi

$246

Buy

39.96%

Upside

Reiterated

06/15/26

Neurocrine: Pipeline De-Risking With Positive Crenessity and Vykat XR Data; Buy Rating Reiterated, $246 Price Target Unchanged

Myles Minter

William Blair

―

Buy

―

Reiterated

06/02/26

Myles Minter Reiterates Buy on Neurocrine, Citing Diversified Commercial Franchise, Robust Ingrezza Growth, and Catalyst-Rich Late-Stage Pipeline

Corinne Johnson

Goldman Sachs

$213

Buy

21.18%

Upside

Initiated

06/02/26

Neurocrine reinstated with a Buy at Goldman SachsNeurocrine reinstated with a Buy at Goldman Sachs

Jeffrey Walch

Bernstein

$221

Buy

25.73%

Upside

Initiated

05/21/26

Neurocrine initiated with an Outperform at BernsteinNeurocrine initiated with an Outperform at Bernstein

Cory Kasimov

Evercore ISI

$210

Buy

19.47%

Upside

Reiterated

05/18/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sean Laaman

Morgan Stanley

$191→$193

Hold

9.80%

Upside

Assigned

07/23/26

Morgan Stanley Issues a Hold Rating on Neurocrine (NBIX)

Yatin Suneja

Guggenheim

$175→$200

Buy

13.79%

Upside

Reiterated

07/21/26

Neurocrine price target raised to $200 from $175 at GuggenheimNeurocrine price target raised to $200 from $175 at Guggenheim

Mohit Bansal

Wells Fargo

$175→$200

Buy

13.79%

Upside

Assigned

07/17/26

Wells Fargo Remains a Buy on Neurocrine (NBIX)

Tazeen Ahmad

Bank of America Securities

$199

Buy

13.22%

Upside

Reiterated

07/15/26

Bank of America Securities Reaffirms Their Buy Rating on Neurocrine (NBIX)

Danielle Brill

Truist Financial

$155→$200

Buy

13.79%

Upside

Reiterated

07/13/26

Neurocrine price target raised to $200 from $155 at TruistNeurocrine price target raised to $200 from $155 at Truist

Laura Chico

Wedbush

$176→$185

Buy

5.25%

Upside

Reiterated

07/13/26

Analysts Are Bullish on These Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Neurocrine (NBIX)

Evan Seigerman

BMO Capital

$144→$170

Hold

-3.28%

Downside

Reiterated

07/13/26

Neurocrine price target raised to $170 from $144 at BMO CapitalNeurocrine price target raised to $170 from $144 at BMO Capital

Brian Abrahams

RBC Capital

$183→$195

Buy

10.94%

Upside

Reiterated

07/07/26

Neurocrine price target raised to $195 from $183 at RBC CapitalNeurocrine price target raised to $195 from $183 at RBC Capital

Akash Tewari

Jefferies

$200

Buy

13.79%

Upside

Reiterated

06/30/26

Neurocrine (NBIX) Receives a Buy from Jefferies

Ashwani Verma

UBS

$182→$208

Buy

18.34%

Upside

Reiterated

06/30/26

Neurocrine price target raised to $208 from $182 at UBSNeurocrine price target raised to $208 from $182 at UBS

Yigal Nochomovitz

Citi

$246

Buy

39.96%

Upside

Reiterated

06/15/26

Neurocrine: Pipeline De-Risking With Positive Crenessity and Vykat XR Data; Buy Rating Reiterated, $246 Price Target Unchanged

Myles Minter

William Blair

―

Buy

―

Reiterated

06/02/26

Myles Minter Reiterates Buy on Neurocrine, Citing Diversified Commercial Franchise, Robust Ingrezza Growth, and Catalyst-Rich Late-Stage Pipeline

Corinne Johnson

Goldman Sachs

$213

Buy

21.18%

Upside

Initiated

06/02/26

Neurocrine reinstated with a Buy at Goldman SachsNeurocrine reinstated with a Buy at Goldman Sachs

Jeffrey Walch

Bernstein

$221

Buy

25.73%

Upside

Initiated

05/21/26

Neurocrine initiated with an Outperform at BernsteinNeurocrine initiated with an Outperform at Bernstein

Cory Kasimov

Evercore ISI

$210

Buy

19.47%

Upside

Reiterated

05/18/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurocrine

3 Months

Jay OlsonOppenheimer

Success Rate

17/25 ratings generated profit

Average Return

+4.43%

Copying Jay Olson's trades and holding each position for 3 Months would result in 68.00% of your transactions generating a profit, with an average return of +4.43% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

16/21 ratings generated profit

Average Return

+11.44%

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 76.19% of your transactions generating a profit, with an average return of +11.44% per trade.

2 Years

Akash TewariJefferies

Success Rate

21/23 ratings generated profit

Average Return

+24.55%

Copying Akash Tewari's trades and holding each position for 2 Years would result in 91.30% of your transactions generating a profit, with an average return of +24.55% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NBIX Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NBIX has received 31 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. NBIX average Analyst price target in the past 3 months is 200.87.

Each month's total comprises the sum of three months' worth of ratings.

NBIX Financial Forecast

NBIX Earnings Forecast

Currently, no earnings data available.

NBIX Sales Forecast

Currently, no sales data available.

NBIX Stock Forecast FAQ

What is NBIX’s average 12-month price target, according to analysts?

Based on analyst ratings, Neurocrine Biosciences’s 12-month average price target is 200.87.

What is NBIX’s upside potential, based on the analysts’ average price target?

Neurocrine Biosciences has 14.28% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NBIX a Buy, Sell or Hold?

Neurocrine Biosciences has a consensus rating of Strong Buy which is based on 21 buy ratings, 3 hold ratings and 0 sell ratings.

What is Neurocrine Biosciences’s price target?

The average price target for Neurocrine Biosciences is 200.87. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $246.00 ,the lowest forecast is $155.00. The average price target represents 14.28% Increase from the current price of $175.77.

What do analysts say about Neurocrine Biosciences?

Neurocrine Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Streets Analysts.

How can I buy shares of NBIX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Neurocrine (NBIX) Stock Forecast & Price Target

NBIX Analyst Ratings

NBIX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Neurocrine

NBIX Analyst Recommendation Trends

NBIX Financial Forecast

NBIX Earnings Forecast

NBIX Sales Forecast

NBIX Stock Forecast FAQ

Detailed List of Analyst Forecasts